From Idea to Market: Ep 11 - Built to Last or Built to Sell?

Send us Fan Mail

Is your med tech company built to last, or built to sell? Voices from inside Stryker, XRSynergies, FIOS Health, and physician contract law explain why exit strategy is a design choice founders make on day one — whether they realize it or not.

In 2024, med tech M&A reached a record $474 billion in global transaction value. For most successful device startups, the path to broad patient reach runs through acquisition — and that reality shapes how experienced founders structure their companies from the moment of incorporation. Corporate form, consulting agreements, equity design, and quality systems all encode an implied destination long before an acquirer ever calls.

Robert Cohen (VP of Innovation & Technology, Stryker Orthopedics) describes how acquisition conversations actually unfold — why the clinical case comes before any discussion of cost of goods or time to market, and how incorporating as a C corporation from day one made his second company's acquisition by Mako Surgical dramatically easier. Marie-Isabelle Batthyány (founder & CEO, XRSynergies) explains building a company that is "easy to take over," from phantom share programs to diligence-ready quality management. Attorney Emily Ast unpacks the shift from long royalty streams toward milestone-based deal structures, and Charles Lawrie (co-founder, FIOS Health) makes the case for clinical validation as the founder's contribution, with commercial scaling left to the acquirer.

Whether you're a surgeon with a device idea, a founder weighing an LLC against a C corporation, or a clinician curious how acquisitions preserve or lose the clinical knowledge behind a product, this episode maps the decisions that determine what your company becomes.

⏱️ Chapters:
00:00 Introduction: exit as a design choice, not a finish line
03:00 Meet the founders, acquirers, and attorneys
05:06 Early structural choices that define what a company becomes
06:04 What a med tech acquirer is actually buying
08:12 How acquisition conversations start: the clinical case first
10:24 Structuring a startup to be acquisition-ready
12:57 Path dependency: early decisions that get expensive to reverse
14:17 Why a C corporation from day one speeds diligence
16:31 Royalties vs milestone payments in med tech deals
19:34 Why acquisitions underperform: knowledge transfer and retention
24:18 Building to sell: clinical validation vs commercial scale

Listen to the AHF Podcast on your preferred platform:
Buzzsprout: https://ahfpodcast.buzzsprout.com
Apple Podcasts: https://podcasts.apple.com/us/podcast/ahf-podcast/id1749521487
Spotify: https://open.spotify.com/show/5CrGJyvRiQFTCU3FFFVvHc
LinkedIn: https://www.linkedin.com/showcase/ahf-podcast
YouTube: https://www.youtube.com/@anteriorhipfoundation
Homepage: https://anteriorhipfoundation.com

This podcast is intended for educational and informational purposes only.

The content discussed does not constitute medical advice and should not be used as a substitute for professional judgment. Clinicians should rely on their own training, experience, and clinical decision-making when applying information from this discussion.

#AnteriorHipFoundation #AHFPodcast #MedTech #MedicalDevices #MedTechAcquisitions #ExitStrategy #MedicalDeviceStartup #OrthopedicSurgery #HealthcareInnovation #DeviceDevelopment #FromIdeaToMarket #Stryker